Tower Research Capital (TRC)’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-7,844
| Closed | -$3K | – | 6559 |
|
|
2023
Q1 | $3K | Sell |
7,844
-3,676
| -32% | -$3.4K | ﹤0.01% | 5291 |
|
|
2022
Q4 | $8K | Buy |
11,520
+1,813
| +19% | +$1.79K | ﹤0.01% | 4512 |
|
|
2022
Q3 | $12K | Buy |
9,707
+3,452
| +55% | +$4.4K | ﹤0.01% | 4406 |
|
|
2022
Q2 | $7K | Buy |
6,255
+2,519
| +67% | +$3.81K | ﹤0.01% | 4861 |
|
|
2022
Q1 | $8K | Buy |
+3,736
| New | +$6.07K | ﹤0.01% | 4647 |
|
|
2021
Q4 | – | Sell |
-302
| Closed | -$1K | – | 6805 |
|
|
2021
Q3 | $1K | Buy |
302
+127
| +73% | +$387 | ﹤0.01% | 5600 |
|
|
2021
Q2 | $1K | Buy |
+175
| New | +$562 | ﹤0.01% | 5313 |
|
|
2021
Q1 | – | Sell |
-4,336
| Closed | -$15K | – | 5867 |
|
|
2020
Q4 | $15K | Buy |
+4,336
| New | +$18.3K | ﹤0.01% | 4073 |
|
|
2020
Q3 | – | Sell |
-7,030
| Closed | -$52K | – | 5206 |
|
|
2020
Q2 | $52K | Sell |
7,030
-5,887
| -46% | -$40.1K | ﹤0.01% | 3022 |
|
|
2020
Q1 | $61K | Buy |
12,917
+12,100
| +1,481% | +$130K | ﹤0.01% | 1203 |
|
|
2019
Q4 | $10K | Buy |
+817
| New | +$7.54K | ﹤0.01% | 2355 |
|
|
2019
Q3 | – | Sell |
-2,463
| Closed | -$42K | – | 4660 |
|
|
2019
Q2 | $42K | Buy |
2,463
+2,309
| +1,499% | +$62.5K | ﹤0.01% | 1716 |
|
|
2019
Q1 | $5K | Sell |
154
-84
| -35% | -$2.81K | ﹤0.01% | 3112 |
|
|
2018
Q4 | $7K | Sell |
238
-49
| -17% | -$2.17K | ﹤0.01% | 2733 |
|
|
2018
Q3 | $18K | Buy |
287
+85
| +42% | +$5.75K | ﹤0.01% | 2431 |
|
|
2018
Q2 | $15K | Sell |
202
-974
| -83% | -$75.9K | ﹤0.01% | 2601 |
|
|
2018
Q1 | $77K | Buy |
+1,176
| New | +$88.8K | 0.01% | 1435 |
|
|
2017
Q4 | – | Sell |
-530
| Closed | -$61K | – | 4182 |
|
|
2017
Q3 | $61K | Buy |
+530
| New | +$55.8K | 0.01% | 1795 |
|
|
2017
Q2 | – | Sell |
-10
| Closed | -$1K | – | 3643 |
|
|
2017
Q1 | $1K | Sell |
10
-530
| -98% | -$69.4K | ﹤0.01% | 2885 |
|
|
2016
Q4 | $73K | Buy |
540
+529
| +4,809% | +$93.9K | 0.01% | 1155 |
|
|
2016
Q3 | $2K | Buy |
+11
| New | +$1.89K | ﹤0.01% | 3167 |
|
|
2016
Q2 | – | Sell |
-174
| Closed | -$16K | – | 5150 |
|
|
2016
Q1 | $16K | Sell |
174
-79
| -31% | -$8.6K | ﹤0.01% | 1525 |
|
|
2015
Q4 | $52K | Buy |
253
+230
| +1,000% | +$41.1K | 0.01% | 543 |
|
|
2015
Q3 | $3K | Sell |
23
-7
| -23% | -$1.28K | ﹤0.01% | 3195 |
|
|
2015
Q2 | $6K | Sell |
30
-181
| -86% | -$44.4K | ﹤0.01% | 3164 |
|
|
2015
Q1 | $49K | Buy |
+211
| New | +$51K | 0.01% | 1486 |
|
Other funds holding BLCM
BC
BRWA
TCM
PGAM
Tower Research Capital (TRC)'s BLCM Position: Q2 2023 in Review
Tower Research Capital (TRC) sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 7,844 shares — an estimated $3K sold.
Tower Research Capital (TRC) first reported a position in BLCM in Q1 2015 and held it in 26 quarters. The position peaked at $77K in Q1 2018. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.
- Tower Research Capital (TRC) reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 7,844 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $3K.
- Tower Research Capital (TRC) first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 26 quarters.
- Tower Research Capital (TRC)'s Bellicum Pharmaceuticals, Inc. position peaked at $77K in Q1 2018.
- 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.